# A Study of Evacetrapib in High-Risk Vascular Disease

> **NCT01687998** · PHASE3 · TERMINATED · sponsor: **Eli Lilly and Company** · enrollment: 12092 (actual)

## Conditions studied

- Cardiovascular Diseases

## Interventions

- **DRUG:** Evacetrapib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01687998
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-10
- **Primary completion:** 2016-03
- **Final completion:** 2016-07
- **Target enrollment:** 12092 (ACTUAL)
- **Why stopped:** Study termination due to insufficient efficacy.
- **Last updated:** 2019-10-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01687998

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01687998, "A Study of Evacetrapib in High-Risk Vascular Disease". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01687998. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*